The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy

Robert I Seed, Alberto J Taurozzi, Daniel J Wilcock, Giovanna Nappo, Holger H H Erb, Martin L Read, Mark Gurney, Leanne K Archer, Saburo Ito, Martin G Rumsby, John L Petrie, Aled Clayton, Norman J Maitland, Anne T Collins

Research output: Contribution to journalArticlepeer-review


Loss of latexin (LXN) expression negatively correlates with the prognosis of several human cancers. Despite association with numerous processes including haematopoietic stem cell (HSC) fate, inflammation and tumour suppression, a clearly defined biological role for LXN is still lacking. Therefore, we sought to understand LXN expression and function in the normal and malignant prostate to assess its potential as a therapeutic target. Our data demonstrate that LXN is highly expressed in normal prostate luminal cells but downregulated in high Gleason grade cancers. LXN protein is both cytosolic and secreted by prostate cells and expression is directly and potently upregulated by all-trans retinoic acid (atRA). Whilst overexpression of LXN in prostate epithelial basal cells did not affect cell fate, LXN overexpression in the luminal cancer line LNCaP reduced plating efficiency. Transcriptome analysis revealed that LXN overexpression had no direct effects on gene expression but had significant indirect effects on important genes involved in both retinoid metabolism and IFN-associated inflammatory responses. These data highlight a potential role for LXN in retinoid signaling and inflammatory pathways. Investigating the effects of LXN on immune cell function in the tumour microenvironment (TME) may reveal how observed intratumoural loss of LXN affects the prognosis of many adenocarcinomas.

Original languageEnglish
Article number5120
Number of pages14
JournalScientific Reports
Issue number1
Publication statusPublished - 26 Mar 2019

Bibliographical note

© The Author(s) 2019

Cite this